Bioprocessing - Upstream & Downstream

Gene therapies look set to revolutionize the field of medicine – and AAVs have emerged as the vector of choice.

How far along is the pharmaceutical industry in its journey with 3D cell culture technologies?

Secretome engineering eliminates unwanted proteins in CHO-based bioprocessing.

How can manufacturing be improved for viral vectors?

Sitting Down With… Mike McMullen, President and CEO, Agilent Technologies, Santa Clara, California, USA.

How are industry and academia collaborating to tackle neglected diseases?

Let’s reduce gene therapy manufacturing costs by optimizing cell lines, improving transfectants, and optimizing downstream purification.

Digital technology, data analytics and continuous processing. The world of biopharma is changing rapidly.

It is time to rethink traditional approaches to biosafety.

We must never forget unmet needs when developing new medicines.